CSIMarket
 
Lexaria Bioscience Corp   (LXRP)
Other Ticker:  
 
 
Price: $0.2898 $-0.00 -1.629%
Day's High: $0.2971 Week Perf: -3.21 %
Day's Low: $ 0.27 30 Day Perf: 2.77 %
Volume (M): 47 52 Wk High: $ 1.00
Volume (M$): $ 14 52 Wk Avg: $0.47
Open: $0.27 52 Wk Low: $0.22



 Market Capitalization (Millions $) 24
 Shares Outstanding (Millions) 83
 Employees 4
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Lexaria Bioscience Corp
Our company’s business plan is currently focused on the development of strategic partnerships with licensees for our patented technology in exchange for up front and/or staged licensing fees over time. Secondarily and more generally, we continue to investigate national and international opportunities for development and distribution of the Company’s enhanced functional food and supplement product offerings; to investigate expansions and additions to our intellectual property portfolio; and, to search for additional opportunities in alternative health sectors. This includes the acquisition or development of intellectual property if and when we believe it advisable to do so. We announced issuance of our first patent by the U.S. Patent and Trademark Office (USPTO) on October 26, 2016 and have received a Notice of Acceptance from the Australian Patent Office with related patent issuance date June 15 2017 No. 2015274698. We announced on November 2, 2017 a new Notice of Allowance from the USPTO that included the delivery of additional molecules such as psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatories, and nicotine all utilizing our DehydraTECHTM delivery technology. We are seeking additional patent protection for what we believe to be a unique process for the nutritional delivery of certain molecules such as cannabinoids, Nicotine, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Vitamins. To achieve sustainable and profitable growth, our company intends to control the timing and costs of our projects wherever possible.


   LXRP is expected to report next financial results on October 12, 2020.
 

Lexaria Bioscience 's Segments
 
 

Nemaura Medical Inc

Nemaura Medical Inc announced fourth quarter operating loss of $-1.346884 millions

In the fourth quarter Nemaura Medical Inc lost money of $-0.01 per share compared to $-0.01 a year ago and improved from $-0.02 per share from the previous quarter.

Sales remained unchanged to $0.00 millions from $0.02 millions in the same quarter a year ago and sequentially from $0.00 millions.

Remedent Inc

Remedent Inc announced fourth quarter operating shortfall of $-0.192893 millions

In the fourth quarter Remedent Inc posted a loss of $-0.02 per share compared to $0.13 a year ago and increased losses from $-0.01 per share from the previous quarter.

Sales faded by -38.03% to $0.25 millions from $0.40 millions in the same quarter a year ago and sequentially Sales decreased by -4.49% from $0.26 millions.

Acura Pharmaceuticals Inc

Acura Pharmaceuticals Inc announced first quarter operating deficit of $-0.483 millions

Acura Pharmaceuticals Inc announced very strong Sales growth of 1528.36% year on year to $1.09 millions in the first quarter, but lost money at $-0.02.

Smg Industries Inc

Smg Industries Inc announced first quarter operating loss of $-2.53214 millions

Smg Industries Inc announced very strong Sales growth of 240.98% year on year to $5.98 millions in the first quarter, but increased losses at $-0.19.

Bionik Laboratories Corp

Break-even, Sales Faded

In the fourth quarter Bionik Laboratories Corp reached break-even of $0.00 per share compared to $0.00 a year ago and from $-0.58 per share from the previous quarter.

Sales crumbled by -27.15% to $0.92 millions from $1.27 millions in the same quarter a year ago and sequentially Sales doubled by 484.34 % from $0.16 millions.






   
Major Competitors Stock performance

5 Days Decrease / Increase
     
• View Complete Report
   



       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ULNV's Profile

Stock Price

ULNV's Financials

Business Description

Fundamentals

Charts & Quotes

ULNV's News

Suppliers

ULNV's Competitors

Customers & Markets

Economic Indicators

ULNV's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071